

Phase 3 Study of MRTX849 +Cetuximab vs Chemo in Patients W/ Advanced Colorectal Cancer w/ KRAS G12C

Status: OPEN TO ACCRUAL

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
- Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.

Exclusion Criteria:

- Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
- Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
- Active brain metastasis

Conditions & Interventions

Interventions:

Drug: MRTX849, Biological: Cetuximab, Drug: mFOLFOX6 Regimen, Drug: FOLFIRI Regimen, drug: Mrtx849, drug: Leucovorin, drug: Folinic acid, drug: Cetuximab, drug: 5-fluorouracil

Conditions:

Advanced Colorectal Cancer, Metastatic Colorectal Cancer, Rectum, Colon

Keywords:

Colorectal Cancer, Colorectal Cancer Trial, Colorectal Carcinoma, Rectal Cancer, Colon Cancer, KRAS, KRAS G12C, RAS, Colorectal Adenocarcinoma

More Information

Contact(s): Donovan, Carrie - cdonovan2@vcu.edu

Principal Investigator: Matin, Khalid

Phase: III

IRB

Number: HM20022574

System ID: NCT04793958

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.